We showed that lenalidomide therapy leads to progression of TP53-mutant CH, which precedes t-MN and t-ALL, while discontinuation of lenalidomide stabilizes CH and may lead to regression of high-risk clones. Here, TP53 is linked to acute lymphoblastic leukemia.